AUPH
Aurinia Pharmaceuticals Inc.
A biopharmaceutical company in Victoria, British Columbia, that develops and sells treatments for autoimmune diseases. Its signature drug, LUPKYNIS (voclosporin), is an oral medicine for adults with lupus nephritis, a kidney inflammation caused by lupus. The company began in 1993 in Edmonton as Isotechnika Pharma, then took the Aurinia name in 2013 when it acquired Aurinia Pharma Corp. and refocused on voclosporin; the drug won US approval in 2021. The brand name Lupkynis blends "lupus" with a distinctive suffix, and "Aurinia" also names a golden-flowered garden plant called basket of gold.
CUSIP: 05156V102HealthcareCA1 holder
Total Value
$283.0K
Total Shares
12.8K
Net Share Change
+12.8K
Activity
1 buying
Investor
Value
Shares
Weight
Change
